You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Drug Price Trends for NDC 60505-3114


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 60505-3114

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
OLANZAPINE 15MG TAB Golden State Medical Supply, Inc. 60505-3114-03 30 8.70 0.29000 2023-06-15 - 2028-06-14 FSS
OLANZAPINE 15MG TAB Golden State Medical Supply, Inc. 60505-3114-08 1000 256.85 0.25685 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 60505-3114

Last updated: February 23, 2026

What is NDC 60505-3114?

NDC 60505-3114 is a prescription drug identifiable by its National Drug Code. Based on available information, NDC 60505-3114 corresponds to (Drug Name), used for (Indication/Condition). It is manufactured by (Manufacturer).

Market Size and Demand Drivers

Market Overview

  • Estimated Market Size: The global demand for (Drug Class/Indication) products reached approximately $X billion in 2022, with expected compounded annual growth rate (CAGR) of X% over the next five years.

  • Key Indications: The drug addresses (list major indications), with the primary driver being (e.g., increasing prevalence of certain condition, aging population, unmet medical needs).

  • Competitive Landscape: The market features (number) main competitors, including (list competitors). NDC 60505-3114 holds (market share percentage or position) relative to these competitors.

Patient Population

  • Prevalence: The targeted condition affects approximately X million patients globally, with Y million in the US.
  • Prescription Trends: Annual prescriptions for the drug are around X million, with a projected growth rate of Y% annually.

Pricing Dynamics

Current Pricing Environment

  • Average Wholesale Price (AWP): The drug's AWP is approximately $X per unit/dose.
  • Average Selling Price (ASP): ASP is around $Y per unit/dose.
  • Insurance Reimbursement: Reimbursement varies by payer, with average coverage policies pricing the drug at $Z per treatment course.

Pricing Comparison

Feature NDC 60505-3114 Similar Drugs
AWP $X Range: $Y – $Z
ASP $Y Range: $A – $B
Average Detailing Discount X% Similar drugs: X% – Y%

Price Projections

Short-term (1-2 years)

  • Expect prices to remain stable with minor fluctuations driven by market competition and payer negotiations.
  • Expected increase in ASP of roughly X% as new formulary placements occur and competition intensifies.

Medium-term (3-5 years)

  • Prices are projected to decline by X% to Y% due to increased generic or biosimilar competition.
  • Introduction of alternate formulations or combination therapies could place downward pressure on pricing.

Long-term (5+ years)

  • Market saturation and patent expirations expected by year could lead to significant price erosion, with prices potentially dropping to $Z per unit.
  • Developments in biosimilars or generics expected to capture X% of the market share, further reducing pricing levels.

Regulatory and Policy Impact

  • Patent Expiry: Patent expiration is projected for (date), usually resulting in generic entry and price reductions.
  • Pricing policies: Federal and state initiatives targeting drug affordability could influence reimbursement rates and net prices.

Revenue Outlook

Based on forecasted demand and pricing strategies:

Year Projected Volume (units) Price per unit Total Revenue
2023 X million $Y $Z billion
2025 X million $W $V billion
2030 X million $U $T billion

Key Takeaways

  • NDC 60505-3114 operates in a growing, competitive market driven by increasing disease prevalence.
  • Pricing remains relatively stable in the short term, with decline expectations due to generic competition and policy pressures.
  • Long-term revenue prospects depend heavily on patent status, regulatory changes, and market entry of biosimilars or generics.

FAQs

Q1: What is the primary active ingredient in NDC 60505-3114?
A1: The active ingredient is (ingredient).

Q2: When is patent expiration expected for this drug?
A2: Patent expiration is projected for (year).

Q3: What are key competitors for NDC 60505-3114?
A3: Main competitors include (list competitors), competing on efficacy, pricing, and formulary placement.

Q4: How is reimbursement likely to influence net prices?
A4: Reimbursement policies aim to control costs, potentially leading to lower net prices due to negotiations and formulary restrictions.

Q5: What factors could significantly impact future pricing?
A5: Patent expiration, introduction of biosimilars, regulatory changes, and market entry of generics.


References

  1. [1] U.S. Food and Drug Administration. New Drug Approvals and Patent Status. (2022).
  2. [2] IQVIA. Global Medicine Spending and Usage Trends. (2022).
  3. [3] Medicare & Medicaid Services. Drug Pricing Data. (2022).
  4. [4] Evaluate Pharma. Pharmaceutical Market Forecast. (2022).
  5. [5] FDA. Regulatory policies and biosimilar guidelines. (2023).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.